{"id":"https://openalex.org/W1484562536","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","title":"Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer","display_name":"Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer","publication_year":2015,"publication_date":"2015-05-01","ids":{"openalex":"https://openalex.org/W1484562536","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","mag":"1484562536"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs14-p5-05-04","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028010756","display_name":"Neil A. O\u2019Brien","orcid":"https://orcid.org/0000-0001-7408-1091","observed_orcids":["https://orcid.org/0000-0001-7408-1091"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil A O'Brien","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045387212","display_name":"Dylan F. Conklin","orcid":"https://orcid.org/0000-0003-4708-0071","observed_orcids":["https://orcid.org/0000-0003-4708-0071"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dylan Conklin","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086954756","display_name":"Michaela Ching","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michaela Ching","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013404372","display_name":"Tong Luo","orcid":"https://orcid.org/0000-0001-5382-7448","observed_orcids":["https://orcid.org/0000-0001-5382-7448"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luo Tong","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039664664","display_name":"Raul Ayala","orcid":"https://orcid.org/0009-0006-1044-2031","observed_orcids":["https://orcid.org/0009-0006-1044-2031"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raul Ayala","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057610416","display_name":"Shawnt Issakhanian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shawnt Issakhanian","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A Hurvitz","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019864381","display_name":"Emmanuelle di Tomaso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Emmanuelle di Tomaso","raw_affiliation_strings":["2Novartis Pharmaceuticals Corporation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Novartis Pharmaceuticals Corporation","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046772134","display_name":"Ronald Linnartz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald Linnartz","raw_affiliation_strings":["3Novartis Pharmaceuticals Corporation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Novartis Pharmaceuticals Corporation","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073989429","display_name":"Richard S. Finn","orcid":"https://orcid.org/0000-0003-2494-2126","observed_orcids":["https://orcid.org/0000-0003-2494-2126"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard S Finn","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032160958","display_name":"Samit Hirawat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Samit Hirawat","raw_affiliation_strings":["2Novartis Pharmaceuticals Corporation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Novartis Pharmaceuticals Corporation","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis J Slamon","raw_affiliation_strings":["1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology/Oncology, David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"9_Supplement","first_page":"P5","last_page":"05"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.010900000110268593,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/everolimus-resistance","display_name":"everolimus resistance","score":0.8180000185966492},{"id":"https://openalex.org/keywords/mtorc1-inhibition","display_name":"mTORC1 inhibition","score":0.8740000128746033},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.8840000033378601},{"id":"https://openalex.org/keywords/ribosomal-protein-s6-phosphorylation","display_name":"S6 phosphorylation","score":0.8090000152587891},{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.9459999799728394},{"id":"https://openalex.org/keywords/mtorc2","display_name":"mTORC2","score":0.6129999756813049},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7279999852180481},{"id":"https://openalex.org/keywords/reverse-phase-protein-array","display_name":"reverse phase protein array","score":0.628000020980835},{"id":"https://openalex.org/keywords/drug-resistance-mechanisms","display_name":"drug resistance mechanisms","score":0.5320000052452087},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.96269291639328},{"id":"https://openalex.org/C2777609662","wikidata":"https://www.wikidata.org/wiki/Q416356","display_name":"PTEN","level":4,"score":0.7835822105407715},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7721624374389648},{"id":"https://openalex.org/C98490376","wikidata":"https://www.wikidata.org/wiki/Q14876060","display_name":"mTORC1","level":4,"score":0.6776583790779114},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6120807528495789},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.599372923374176},{"id":"https://openalex.org/C2775860665","wikidata":"https://www.wikidata.org/wiki/Q418819","display_name":"Exemestane","level":5,"score":0.536693274974823},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.5167862176895142},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5116048455238342},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.509212851524353},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3110601305961609},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3104107975959778},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.26564061641693115},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.25288569927215576},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.1111905574798584},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.05778804421424866}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs14-p5-05-04","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p5-05-04","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2081793436","https://openalex.org/W2810972083","https://openalex.org/W2734051186","https://openalex.org/W2130542734","https://openalex.org/W2796421332","https://openalex.org/W2313394748","https://openalex.org/W2018133940","https://openalex.org/W2039657950","https://openalex.org/W2069765071","https://openalex.org/W2399894446"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,367],"addition":[3],"of":[4,35,59,199,221,244,256,274,280,299,303,311,335,346,359,374,388,424,436,453,467,507,515,522],"the":[5,33,57,68,210,215,229,235,250,312,325,332,351,363,371,389,405,422,465,468,523],"selective":[6],"mTORC1":[7,337,508],"inhibitor":[8],"everolimus":[9,107,158,175,180,264,444,504],"(RAD001/Afinitor\u00ae),":[10],"to":[11,47,53,66,92,106,114,234,263,272,291,331,403,442,503],"exemestane":[12],"significantly":[13,218],"prolongs":[14],"progression":[15],"free":[16],"survival":[17],"in":[18,77,96,228,242,261,265,288,309,350,362,386,409,440,510,512],"patients":[19,36],"with":[20,152],"advanced":[21],"hormone":[22],"receptor":[23],"(ER+)":[24],"positive":[25],"breast":[26,98,126,517],"cancer.":[27],"However,":[28],"despite":[29,450],"these":[30,78,410,425],"improved":[31],"outcomes,":[32],"majority":[34],"that":[37,103,110,134,317,323,419,433],"achieve":[38],"an":[39],"initial":[40],"clinical":[41],"benefit":[42],"will":[43,461],"eventually":[44],"go":[45],"on":[46,249,320],"develop":[48,439],"progressive":[49],"disease.":[50],"In":[51,81,214],"order":[52],"prevent":[54],"or":[55,155],"delay":[56],"onset":[58],"this":[60,82],"acquired":[61,112,329],"resistance,":[62],"it":[63],"is":[64,74,339],"essential":[65],"identify":[67,416],"mechanisms":[69],"by":[70,296],"which":[71,293],"continued":[72,451],"proliferation":[73,258,423],"being":[75,341],"driven":[76],"resistant":[79,176,353,365,426],"tumors.":[80,182,427],"study,":[83],"we":[84],"used":[85],"reverse":[86],"phase":[87],"protein":[88],"array":[89],"(RPPA)":[90],"technology":[91],"compare":[93],"cell":[94,100,128,184],"signaling":[95,205,247,338,382,391,417],"ER+":[97,125,516],"cancer":[99,127,518],"line":[101],"xenografts":[102],"were":[104,121,149,168,186,207,226,318,384],"responsive":[105,181],"versus":[108],"those":[109],"had":[111],"resistance":[113,330,437,447,502],"everolimus.":[115],"Materials":[116],"and":[117,140,145,178,191,224,314,399,446],"Methods:":[118],"Xenograft":[119],"models":[120,269,514],"established":[122],"from":[123,170,174,179,188,457],"three":[124],"lines":[129],"containing":[130],"different":[131],"molecular":[132,252],"alterations":[133],"confer":[135],"activated":[136],"PI3K/mTOR":[137,454],"signaling;":[138],"MCF7":[139,315,364],"KPL-1":[141,368],"(both":[142],"PIK3CA":[143,236],"mutant)":[144],"ZR75-1":[146,231,313,352],"(PTEN-null).":[147],"Mice":[148],"treated":[150],"daily":[151],"either":[153],"vehicle":[154,171,216],"10":[156],"mg/kg":[157],"until":[159,276],"progression.":[160,281],"Snap":[161],"frozen":[162],"tissue":[163],"samples":[164],"(n":[165],"=":[166],"3)":[167],"collected":[169],"control":[172],"tumors,":[173,238],"tumors":[177,232,277,289,316,411],"Whole":[183],"lysates":[185],"prepared":[187],"tumor":[189,257,326],"tissues":[190],"processed":[192],"for":[193,209,270],"RPPA":[194,211],"analysis.":[195,212],"A":[196,473,486],"customized":[197],"panel":[198],"27":[200],"known":[201],"cancer/PI3K":[202],"pathway":[203,246,376],"associated":[204],"proteins":[206,392],"selected":[208],"Results:":[213],"controls,":[217],"higher":[219],"levels":[220],"pAKT,":[222],"pPRAS40":[223],"p4EBP1":[225],"detected":[227],"PTEN-null":[230],"compared":[233],"mutant":[237],"indicating":[239,322],"potential":[240],"variations":[241],"intensity":[243],"PI3K/AKT":[245],"depending":[248],"initiating":[251],"alteration.":[253],"Complete":[254],"inhibition":[255,302,377,452,509],"was":[259,286,294,306,348],"observed":[260,287,308,349,385],"response":[262,441],"all":[266],"3":[267],"xenograft":[268],"up":[271],"7-weeks":[273],"treatment,":[275],"showed":[278,370],"signs":[279],"Significantly":[282],"lower":[283],"S6":[284,304,375],"phosphorylation":[285,305],"responding":[290],"everolimus,":[292,321,336],"accompanied":[295],"feedback":[297,357],"activation":[298,345,358],"pAKT.":[300],"Significant":[301],"also":[307],"each":[310],"progressing":[319],"although":[324],"cells":[327],"have":[328],"anti-proliferative":[333],"activity":[334],"still":[340],"successfully":[342],"blocked.":[343],"Feedback":[344],"pAKT":[347],"model,":[354],"however":[355],"no":[356],"AKT":[360],"occurred":[361],"model.":[366],"model":[369],"expected":[372],"loss":[373],"upon":[378],"resistance.":[379],"No":[380],"significant":[381],"changes":[383,408],"any":[387],"other":[390],"measured,":[393],"including":[394],"ER,":[395],"HER2,":[396],"EGFR,":[397],"MEK":[398],"ERK.":[400],"Ongoing":[401],"studies":[402],"measure":[404],"mRNA":[406,413,458],"expression":[407],"using":[412],"microarrays":[414],"may":[415],"pathways":[418,435],"are":[420],"driving":[421],"Discussion:":[428],"These":[429],"preclinical":[430,511],"data":[431],"show":[432],"multiple":[434],"can":[438,448],"long-term":[443],"treatment":[445],"occur":[449],"signaling.":[455],"Data":[456],"microarray":[459],"experiments":[460],"be":[462],"presented":[463],"at":[464],"time":[466],"meeting.":[469],"Citation":[470],"Format:":[471],"Neil":[472],"O'Brien,":[474],"Dylan":[475],"Conklin,":[476],"Michaela":[477],"Ching,":[478],"Luo":[479],"Tong,":[480],"Raul":[481],"Ayala,":[482],"Shawnt":[483],"Issakhanian,":[484],"Sara":[485],"Hurvitz,":[487],"Emmanuelle":[488],"di":[489],"Tomaso,":[490],"Ronald":[491],"Linnartz,":[492],"Richard":[493],"S":[494],"Finn,":[495],"Samit":[496],"Hirawat,":[497],"Dennis":[498],"J":[499],"Slamon.":[500],"Acquired":[501],"occurs":[505],"independently":[506],"vivo":[513],"[abstract].":[519],"In:":[520],"Proceedings":[521],"Thirty-Seventh":[524],"Annual":[525],"CTRC-AACR":[526],"San":[527,535],"Antonio":[528],"Breast":[529],"Cancer":[530,541],"Symposium:":[531],"2014":[532],"Dec":[533],"9-13;":[534],"Antonio,":[536],"TX.":[537],"Philadelphia":[538],"(PA):":[539],"AACR;":[540],"Res":[542],"2015;75(9":[543],"Suppl):Abstract":[544],"nr":[545],"P5-05-04.":[546]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}